All currently available antiplatelet drugs viz- Aspirin, PLAVIX(r) ,
Persantine, Aggrastat, and Ticlid are toxic. The CAPRIE (1996) study
showed that the largest selling antiplatelet drugs PLAVIX(r)
(Clopidogrel) and Aspirin are quite toxic with over 50% of those who
take either of them suffer from various toxic side effects. Of course,
the added attraction for PLAVIX(r) is high cost, especially for the
non-responders without any effect on platelet aggregation.

Side Effect and complications of PLAVIX(r) (Clopidogrel) & Aspirin
respectively (CAPRIE STUDY) are:
–Incidence of gastrointestinal events: 27.1% PLAVIX(r); 29.8% Aspirin
–Incidence of skin and appendage disorders: 15.8 % PLAVIX(r); 13.1% Aspirin
–Cases of diarrhea: 4.5 % PLAVIX(r); 3.4% Aspirin
–Gastrointestinal hemorrhage s: 2.0 % PLAVIX(r); 2.7% Aspirin
–Gastrointestinal hemorrhage required hospitalization: 0.7 %
PLAVIX(r); 1.1% Aspirin
–Incidence of peptic, gastric or duodenal ulcers: 0.7 % PLAVIX(r); 1.2% Aspirin
–Incidence of intracranial hemorrhage: 0.4 % PLAVIX(r); 0.5% Aspirin
–Total incidence of side effects: 51.2% PLAVIX(r); 51.8% Aspirin

Mr. Sambaru Prasad, CEO, Lipicard Technologies said, “PLATROL(r) is
the first anti-platelet drug, which promises no gastric irritation or
related side effects. In gastric mucosa irritation animal toxicology
study, 60% of rats were affected with gastric irritation at 200mg/kg
and 300mg/kg dose of Aspirin, whereas, PLATROL(r) affected none of the
rats in either of those equivalent dosages.”

PLATROL(r) was found to be less toxic than Aspirin in the 28-day
animal toxicology study as well. A few animals treated with Aspirin
showed mild fatty changes in the cardiac muscle fibers of heart and
mild catarrhal changes of gastric mucosa, whereas, none of the animals
treated with PLATROL(r) showed any such change.

The molecular structure and mechanism of action of PLATROL(r) is
responsible for selective antiplatelet activity without the side
effect, according to Mr. Prasad.